Clinical trial
A Phase 1 Multi-Center Study to Measure the Pharmacokinetics of Oral Omadacycline in Adult Subjects With Community-Acquired Bacterial Pneumonia (CABP)
NCT04160260 is registered in ClinicalTrials.gov with Paratek Pharmaceuticals Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Multi-Center Study to Measure the Pharmacokinetics of Oral Omadacycline in Adult Subjects With Community-Acquired Bacterial Pneumonia (CABP)
- Lead sponsor
- Paratek Pharmaceuticals Inc
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 28, 2019
- Completion date
- April 13, 2020
- Enrollment
- 18 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.